Stock CYTH CYCLO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.51 USD +2.72% Intraday chart for Cyclo Therapeutics, Inc. +19.84% -5.03%
May. 01 HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target MT
Mar. 18 Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Cyclo Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

84903f8f7c24c23a8.ENZCKWmR0KKJqZSYd9LkEi6drA1OE0t1zsqqg8PBIe4.Qr53QDrrisnzmqH9PoiwJkSs-EIRQB1Ampni1LmWUdx6mxYYW9KGkLH8_w~a6a6dce646edb3eee94de828ca118174

Analyst Recommendations on Cyclo Therapeutics, Inc.

HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target MT
Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target MT
Maxim Group Downgrades Cyclo Therapeutics to Hold From Buy MT
Maxim Group Adjusts Cyclo Therapeutics Price Target to $10 From $16, Maintains Buy Rating MT
CYCLO THERAPEUTICS : Maxim Group Starts Cyclo Therapeutics at Buy With $12 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.51 USD
Average target price
3.2 USD
Spread / Average Target
+111.92%
High Price Target
4 USD
Spread / Highest target
+164.90%
Low Price Target
2.6 USD
Spread / Lowest Target
+72.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cyclo Therapeutics, Inc.

HC Wainwright
Maxim

Ratings for Cyclo Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CYTH Stock
  4. Consensus Cyclo Therapeutics, Inc.